Ionis Pharma has brough antisense therapy to the clinic. Unfortunately, they recently received a complete response letter from the FDA regarding their latest medicine, Waylivra for the treatment of familial chylomicronemia syndrome. In this video, I talk about antisense therapy and the potential way forward for the company. For a complete writeup, check out the post here - Follow me on twitter @matthewlepoire this is not investment advice Links: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM606857.pdf http://ir.ionispharma.com/news-releases/news-release-details/akcea-and-ionis-receive-complete-response-letter-waylivra-fda http://ir.ionispharma.com/static-files/7e19a292-b451-41ef-9e14-4449962c6464